XGX Pharma ApS: Financial statements 2013
CVR: 32289290
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 144,613 and a net result of DKK 144,707 compared with DKK 96,450 the year before. That is an increase of 72.6% compared with the year before. Equity in the 2013 report amounted to DKK 130,429. The solvency ratio was 902.1%.
- Gross Profit
- DKK 144,613
- Profit/Loss
- DKK 144,707
- Equity
- DKK 130,429
- Total Assets
- DKK 14,459
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | 145 t. | 145 t. | 130 t. | - |
| 2012 | - | 84 t. | 96 t. | -14 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
XGX Pharma ApS has published its annual report for 2012. Gross profit came to DKK 83,774, and the net result was DKK 96,450.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.